Yale Comprehensive Cancer Center Support Grant

耶鲁大学综合癌症中心支持补助金

• 批准号: 8917569
• 负责人: Thomas James Lynch
• 金额: $ 33.3万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8917569
• 关键词: Aftercare; Basic Science; Biometry; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Hospital; Cancer Immunology Science; Cancer Patient; Caring; Cesium; Clinical; Clinical Sciences; Clinical Trials; Comprehensive Cancer Center; Development; Developmental Therapeutics Program; Education; Epidemiology; Etiology; Evaluation; Flow Cytometry; Fostering; Funding; Goals; Growth; Hospitals; Institutes; Instruction; Leadership; Malignant Neoplasms; Mission; Molecular; Molecular Virology; Morbidity - disease rate; Pain; Pathology; Patient Care; Patients; Population; Population Sciences; Prevention; Process; Publishing; Radiation therapy; Radiobiology; Recruitment Activity; Research; Research Personnel; Resource Sharing; Scientist; Services; Signal Transduction; Strategic Planning; Therapeutic Clinical Trial; Tissues; Training; Translating; Translational Research; United States; Yale Cancer Center; anticancer research; cancer genetics; cancer genomics; cancer prevention; clinical care; end of life; genome analysis; improved; member; mortality; multidisciplinary; next generation; palliative; patient oriented; programs; screening; survivorship; tumor immunology

DESCRIPTION (provided by applicant): The core mission of the Yale Cancer Center is to reduce suffering from cancer by being a global leader in cancer research, care and education. Designated as a Comprehensive Cancer Center in 1974, the past five years have been a period of significant growth and restructuring. Dr. Thomas Lynch became the 6th Director of the YCC in April 2009 and recruited more than 80 new basic, population, translational and clinical scientists. In addition to appointing a new Deputy Director, Dr. Daniel DiMaio, Senior Leadership and cancer Center Administration was completely redesigned. For this submission 6 of 7 Research Programs are under new leadership. During the most recent funding period, the YCCs 260 members published 2751 articles, (21% intra-programmatic and 14% inter-programmatic) and hold $93M in total cancer funding (including $29M from NCI). Accrual to therapeutic clinical trials more than doubled over the past year. Driven by remarkable institutional support, significant expansion during the prior funding period included building the $450M Smilow Cancer Hospital, opening 7 regional Care Centers in Southern CT and acquiring the former Hospital St. Raphael to create the nation's 4th largest hospital. This clinical care expansion was matched by establishing the Yale Cancer Biology Institute at Yale's West Campus. A detailed strategic planning process has begun with a resultant strong emphasis on optimizing our research programs and shared resources and investing in translational research, cancer genetics, and tumor immunology. This 5-year request is to support an organizational framework that promotes and fosters basic and translational cancer research. The 7 Research Programs include: Cancer Genetics and Genomics, Cancer Immunology, Cancer Prevention and Control, Developmental Therapeutics, Molecular Virology, Radiobiology and Radiotherapy and Signal Transduction. Support is requested for 8 Shared Resources including Yale Center for Genome Analysis, Flow Cytometry, Yale Pathology Tissue Services, Cesium Irradiator, Rapid Case Ascertainment, Yale Center for Molecular Discovery, Biostatistics and the Clinical Trials Office. To support center goals and objectives support for Senior Leadership, Planning and Evaluation, Administration, and Developmental Funds is also requested.

描述（由申请人提供）：耶鲁癌症中心的核心使命是通过成为癌症研究，护理和教育的全球领导者来减少癌症的痛苦。 1974年，过去五年被指定为综合癌症中心，是一个显着增长和重组的时期。托马斯·林奇（Thomas Lynch）博士于2009年4月成为YCC的第六任主任，并招募了80多位新的基本，人口，转化和临床科学家。 除任命新的副主任丹尼尔·迪马奥（Daniel Dimaio）博士外，高级领导力和癌症中心管理局还完全重新设计了。对于这项提交的6个研究计划中的6个研究计划都在新的领导下。在最近的资金期间，YCCS的260名成员发表了2751篇文章（21％的杂志内和14％的程序间编程），总共持有9300万美元的癌症资金（包括NCI的2900万美元）。在过去的一年中，对治疗性临床试验的应计倍增。在大量机构支持的驱动下，在上一家资金期间的显着扩张包括建立了4.5亿美元的Smilow Cancer Hospital，在CT南部开设了7个区域护理中心，并收购了前圣拉斐尔医院以创建美国第四大医院。通过在耶鲁大学西部校园建立耶鲁大学癌症生物学研究所的临床护理扩展是相匹配的。详细的战略规划过程已经开始，因此非常强调优化我们的研究计划，共享资源并投资于转化研究，癌症遗传学和肿瘤免疫学。这个为期5年的要求是支持促进和培养基础和转化癌症研究的组织框架。 7个研究计划包括：癌症遗传学和基因组学，癌症免疫学，预防和控制，发育疗法，分子病毒学，放射性生物学和放疗以及信号转导。请求支持8个共享资源，包括耶鲁大学基因组分析中心，流式细胞仪，耶鲁大学病理组织服务，铯辐照器，快速案例确定，耶鲁大学分子发现中心，生物统计学和临床​​试验办公室。还要求为中心目标和目标提供支持，以支持高级领导，计划和评估，管理和发展基金。